Table 3. Acceptability and feasibility of lupus nephritis decision aid versus lupus pamphlet and feasibility of the study procedures.
| Acceptability and Feasibility Assessments | Decision Aid | Pamphlet | p-value** |
|---|---|---|---|
| (n = 151) | (n = 147) | ||
| Patient acceptability of information and presentation: Percentage of subjects marking "Excellent” | |||
| Impact of lupus nephritis | 74 (49.0%) | 49 (33.0%) | 0.006 |
| Risk factors | 64 (42.4%) | 40 (27.2%) | 0.006 |
| Medication options | 76 (50.3%) | 49 (33.3%) | 0.003 |
| Evidence about medications | 71 (47.0%) | 35 (23.8%) | <0.001 |
| Studies about others | 64 (42.4%) | 32 (21.8%) | <0.001 |
| Feasibility of the study intervention | |||
| The education guide*was easy to use. | 0.006 | ||
| (Missing) | — | 1 (0.7%) | |
| Strongly Disagree | 1 (0.7%) | 3 (2.0%) | |
| Disagree | 1 (0.7%) | 13 (8.8%) | |
| Neither Agree nor Disagree | 73 (48.3%) | 74 (50.3%) | |
| Agree | 75 (49.7%) | 55 (37.4%) | |
| Strongly Agree | 1 (0.7%) | 1 (0.7%) | |
| Feasibility of the study procedures | |||
| The questions were easy to see/hear. | 0.70 | ||
| (Missing) | — | 1 (0.7%) | |
| Strongly Disagree | 1 (0.7%) | 2 (1.4%) | |
| Disagree | 5 (3.3%) | 3 (2.0%) | |
| Neither Agree nor Disagree | 5 (3.3%) | 7 (4.8%) | |
| Agree | 70 (46.4%) | 75 (51.0%) | |
| Strongly Agree | 70 (46.4%) | 59 (40.1%) | |
| The questions were easy to answer. | 0.10 | ||
| (Missing) | — | 1 (0.7%) | |
| Strongly Disagree | 1 (0.7%) | 3 (2.0%) | |
| Disagree | 3 (2.0%) | 9 (6.1%) | |
| Neither Agree nor Disagree | 18 (11.9%) | 27 (18.4%) | |
| Agree | 73 (48.3%) | 63 (42.9%) | |
| Strongly Agree | 56 (37.1%) | 44 (29.9%) | |
| The process did not take too long. | 0.23 | ||
| (Missing) | — | 1 (0.7%) | |
| Strongly Disagree | 4 (2.6%) | 3 (2.0%) | |
| Disagree | 25 (16.6%) | 13 (8.8%) | |
| Neither Agree nor Disagree | 22 (14.6%) | 29 (19.7%) | |
| Agree | 56 (37.1%) | 63 (42.9%) | |
| Strongly Agree | 44 (29.1%) | 38 (25.8%) | |
| I did not mind spending extra time at my doctor visit to understand the risks and benefits of treatment. | 0.23 | ||
| (Missing) | — | 1 (0.7%) | |
| Strongly Disagree | 1 (0.7%) | 4 (2.7%) | |
| Disagree | 6 (4.0%) | 1 (0.7%) | |
| Neither Agree nor Disagree | 12 (7.9%) | 13 (8.8%) | |
| Agree | 63 (41.7%) | 57 (38.8%) | |
| Strongly Agree | 69 (45.7%) | 71 (48.3%) |
*Education guide refers to the ACR pamphlet or the computerized, individualized decision aid.
**p-value using chi-squared test.
Each question is in italics.
Abbreviation: ACR, American College of Rheumatology.